Celldex Therapeutics Hits New 52-Week High at $31.00

Celldex Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 31.00 on February 25, 2026. This achievement marks a notable increase from its 52-week low of USD 14.40, reflecting a substantial upward movement in the stock's performance over the past year. Despite this recent high, Celldex's one-year performance stands at -11.03%, contrasting sharply with the S&P 500's gain of 12.95% during the same period. The company's market capitalization is currently valued at USD 1,530 million, indicating its position as a small-cap entity within the industry. Financial metrics reveal that Celldex is currently loss-making, with a return on equity of -37.52% and a debt-to-equity ratio of -0.96. The stock does not offer a dividend yield, and its price-to-book ratio stands at 2.56. As Celldex Therapeutics continues to navigate the competitive landscape of pharmaceuticals and biotechnology, this new high underscores its recent activity in the market.